FRI0024 Do age and education influence the disease activity score? an explorative analysis in the norwegian cohort study nor-dmard

Background While ageing influences auto-immune inflammation and the structure of the joints, knowledge about its influence on appraisal of disease outcomes is more limited. Objectives To examine the effect of age and education on the components of the 28-joint Disease Activity Score (DAS28-ESR) in patients with rheumatoid arthritis (RA). Methods Baseline data of Disease Modifying Anti-Rheumatic Drug (DMARD)-naive patients with RA from the Norwegian Register of DMARDs (NOR-DMARD) were used. Linear regression models, adjusted for gender and education (low, intermediate and high level), were used to investigate the strength of the association between age ( 65 years) and each DAS28-component (Erythrocyte Sedimentation Rate (ESR), 28-tender joint count (28-TJC), 28-swollen joint count (28-SJC), and patient global assessment of disease activity (PGA)). Adjusted scores for components of DAS28 and total DAS28-ESR were computed and relative change across age categories was explored. Interactions between age and gender and age and education were also tested. Results Baseline data from 2037 patients (mean (SD) age 55.2 (14.0) years, 68% female) were available. Regression models were stratified for gender (p –interaction 65 years) with an intermediate level of education would have a 21% higher ESR and 14% higher 28-SJC, as compared to their younger counterparts ( 65 years was 4.8 compared to 4.3 in patients Conclusions As expected, DAS28 increases with age. However, the components of DAS28 increase at different rates. The age-related increase in ESR and 28-SJC without a simultaneous increase in 28-TJC and PGA might imply that age-related processes (e.g. osteoarthritis and physiological increase in ESR) drive the DAS28 in older patients. The observed patterns were largely comparable between males and females. The age effect on DAS28 is relevant in a treat-to-target strategy and may be considered when identifying a defined target in individual patients. Disclosure of Interest None declared